Myriad Genetics (MYGN) Other Accumulated Expenses (2014 - 2020)

Myriad Genetics (MYGN) has reported Other Accumulated Expenses for 7 consecutive years, with $22.4 million the latest figure, recorded in Q2 2020.

• In Q2 2020, Other Accumulated Expenses rose 24.44% year-over-year to $22.4 million; the TTM figure through Jun 2020 stood at $22.4 million (up 24.44% YoY), while the FY2020 annual figure was $22.4 million, up 24.44% from the prior year.
• Other Accumulated Expenses improved to $22.4 million in Q2 2020 per MYGN's latest filing, from $4.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $22.4 million in Q2 2020 and bottomed at $4.3 million in Q1 2020.
• Historically, Other Accumulated Expenses has averaged $14.0 million across 5 years, with a median of $14.0 million in 2017.
• Annual changes were most pronounced in 2016 — Other Accumulated Expenses surged 84.81% — and 2020, when it plunged 80.09%.
• Myriad Genetics' Other Accumulated Expenses stood at $13.7 million in 2016, then grew by 13.87% to $15.6 million in 2017, then increased by 13.46% to $17.7 million in 2018, then slumped by 53.67% to $8.2 million in 2019, then jumped by 173.17% to $22.4 million in 2020.
• Business Quant data shows MYGN's Other Accumulated Expenses at $22.4 million in Q2 2020, $4.3 million in Q1 2020, and $8.2 million in Q4 2019.